
Goldman Sachs literally published a report warning investors that curing diseases is bad for long-term corporate cash flow.
i used to roll my eyes when people said pharmaceutical companies would rather treat symptoms forever than actually cure a disease. it sounded like standard internet paranoia.
but then i found an actual research report from Goldman Sachs from april 2018, and it’s honestly one of the most bleak things i’ve ever read. they say the quiet part out loud: curing people is bad for long-term cash flow.
the report is called "The Genome Revolution" (written by analyst Salveen Richter). in it, they explicitly ask the question: "Is curing patients a sustainable business model?"
they didn't just ask the question; they provided a real-world case study to warn investors. they used Gilead Sciences and their Hepatitis C drugs (Sovaldi and Harvoni) as the ultimate cautionary tale.
here is the actual financial timeline:
• in 2015, Gilead released a genuine medical miracle. their new drugs had a Hepatitis C cure rate of over 90%.
• because the drug was incredible, their us revenue absolutely skyrocketed to $12.5 billion that year.
• but because the drug actually worked, they rapidly shrank the pool of infected people. they basically cured their own customer base.
• by 2018, Goldman estimated their us sales for those treatments would plummet to under $4 billion. (actual revenue reports confirmed this massive slide).
Goldman’s takeaway for investors? "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines... this could represent a challenge for genome medicine developers looking for sustained cash flow."
they even point out that treatments for chronic conditions pose "less risk to the sustainability of a franchise."
it’s not a cartoon villain conspiracy. it’s just the cold, hard math of fiduciary duty. a patient who needs a daily pill for 40 years is a highly valued recurring revenue stream. a patient who is cured in 30 days is a financial loss. we've built a system where the ultimate medical triumph is actively punished by the stock market.
sources if you want to read the financial breakdown:
• CNBC covering the GS report: https://www.cnbc.com/2018/04/11/goldman-asks-is-curing-patients-a-sustainable-business-model.html
• bio pharma dive covering the revenue crash: https://www.biopharmadive.com/news/gilead-hepatitis-c-revenues-slide-fourth-quarter-earnings/516494/
